Cargando…
One-year results of treat-and-extend regimen with intravitreal brolucizumab for treatment-naïve neovascular age-related macular degeneration with type 1 macular neovascularization
We evaluated 1-year outcomes of loading phase treatment followed by maintenance treatment using a treat-and-extend (TAE) regimen with intravitreal brolucizumab for neovascular age-related macular degeneration (nAMD) associated with type 1 macular neovascularization (MNV). We analyzed 68 eyes of 65 c...
Autores principales: | Matsumoto, Hidetaka, Hoshino, Junki, Mukai, Ryo, Nakamura, Kosuke, Akiyama, Hideo |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group UK
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9114020/ https://www.ncbi.nlm.nih.gov/pubmed/35581196 http://dx.doi.org/10.1038/s41598-022-10578-1 |
Ejemplares similares
-
Two-year outcomes of treat-and-extend regimen with intravitreal brolucizumab for treatment-naïve neovascular age-related macular degeneration with type 1 macular neovascularization
por: Matsumoto, Hidetaka, et al.
Publicado: (2023) -
Short-term outcomes of intravitreal brolucizumab for treatment-naïve neovascular age-related macular degeneration with type 1 choroidal neovascularization including polypoidal choroidal vasculopathy
por: Matsumoto, Hidetaka, et al.
Publicado: (2021) -
Clinical characteristics and pachychoroid incidence in Japanese patients with neovascular age-related macular degeneration
por: Matsumoto, Hidetaka, et al.
Publicado: (2022) -
Risk factors for emerging intraocular inflammation after intravitreal brolucizumab injection for age-related macular degeneration
por: Mukai, Ryo, et al.
Publicado: (2021) -
Intravitreal Brolucizumab for Neovascular Age-Related Macular Degeneration in a Vitrectomized Eye
por: Maggio, Emilia, et al.
Publicado: (2022)